JUNS
NASDAQJupiter Neurosciences Inc.
Price$0.23+0.00 (+1.30%)
01:30 PM07:30 PM
News · 26 weeks52+550%
2025-12-142026-06-07
Mix3890d
- SEC Filings15(39%)
- Other10(26%)
- Insider9(24%)
- Offering2(5%)
- Leadership1(3%)
- Market1(3%)
Latest news
25 items- PRPresenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live streamMIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday June 11, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered,
- SECSEC Form PRE 14A filed by Jupiter Neurosciences Inc.PRE 14A - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRPresenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live streamMIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJune 10, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- INSIDERSEC Form 4 filed by Director Brady Allison W4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Hayward Marshall A.4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Elmasri Saleem4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Silva Alison D.4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Director Kampf Julie B.4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Director Hemmerly Nicholas H.4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by CEO and Chairman Rosen Christer4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Director Weis Holger4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERSEC Form 4 filed by Chief Administrative Officer Rosen Alexander Gustaf Erik4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- PRJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's DiseaseInvestigational Oral Candidate JOTROL™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson's Disease (PD), with first patient dosing expected in the near term. Parkinson's Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new
- NEWSD. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct OfferingNEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").D. Boral Capital LLC acted as the Exclusive Placement Agent for the Offering.The shares of common stock were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declare
- PRJupiter Neurosciences Announces Closing of $2.0 Million Registered Direct OfferingCash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering"). "Yesterday's capital raise helps the Company p
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECSEC Form 424B5 filed by Jupiter Neurosciences Inc.424B5 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingJupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions. T
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRPharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 MillionTORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE:MDMA, OTCQB:MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the "Term Sheet") under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter") exclusive, perpetual United States licensing rights to ALA-002, PharmAla's lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development milestone pa
JUNS FAQ
5 questionsWhere does JUNS stock trade?
Jupiter Neurosciences Inc. (JUNS) is listed on NASDAQ.What sector and industry is JUNS in?
Jupiter Neurosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Jupiter Neurosciences Inc. go public?
Jupiter Neurosciences Inc. (JUNS) completed its IPO in 2024.What companies are similar to JUNS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare JUNS side-by-side with any of them on Quantisnow.How can I track JUNS on Quantisnow?
Quantisnow aggregates Jupiter Neurosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JUNS to receive live email and push alerts on every new disclosure.